CN110384720A - A kind of hippophae rhamnoides compositions and its preparation method and application - Google Patents
A kind of hippophae rhamnoides compositions and its preparation method and application Download PDFInfo
- Publication number
- CN110384720A CN110384720A CN201810343377.5A CN201810343377A CN110384720A CN 110384720 A CN110384720 A CN 110384720A CN 201810343377 A CN201810343377 A CN 201810343377A CN 110384720 A CN110384720 A CN 110384720A
- Authority
- CN
- China
- Prior art keywords
- hippophae
- hippophae rhamnoides
- auxiliary material
- leaves
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003145 Hippophae rhamnoides Nutrition 0.000 title claims abstract description 58
- 240000000950 Hippophae rhamnoides Species 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims description 25
- 239000000463 material Substances 0.000 claims abstract description 55
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 14
- 229930195725 Mannitol Natural products 0.000 claims abstract description 14
- 239000000594 mannitol Substances 0.000 claims abstract description 14
- 235000010355 mannitol Nutrition 0.000 claims abstract description 14
- 229920002472 Starch Polymers 0.000 claims abstract description 9
- 239000008107 starch Substances 0.000 claims abstract description 9
- 235000019698 starch Nutrition 0.000 claims abstract description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 8
- 229930195727 α-lactose Natural products 0.000 claims abstract description 8
- 241000229143 Hippophae Species 0.000 claims description 63
- 235000003935 Hippophae Nutrition 0.000 claims description 45
- 238000000605 extraction Methods 0.000 claims description 41
- 239000000284 extract Substances 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- 235000019441 ethanol Nutrition 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 11
- 239000000853 adhesive Substances 0.000 claims description 10
- 230000001070 adhesive effect Effects 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- 235000013339 cereals Nutrition 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 abstract description 48
- 229940126678 chinese medicines Drugs 0.000 abstract 1
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 36
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 35
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 34
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 23
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 23
- 235000008800 isorhamnetin Nutrition 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 18
- 235000008777 kaempferol Nutrition 0.000 description 18
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 18
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 16
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 16
- 235000005875 quercetin Nutrition 0.000 description 16
- 229960001285 quercetin Drugs 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 11
- 239000008187 granular material Substances 0.000 description 10
- 238000011835 investigation Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000012795 verification Methods 0.000 description 7
- 229920001353 Dextrin Polymers 0.000 description 6
- 239000004375 Dextrin Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000019425 dextrin Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 244000062250 Kaempferia rotunda Species 0.000 description 3
- 235000013422 Kaempferia rotunda Nutrition 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- -1 flavone compound Chemical class 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 2
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 2
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 2
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000005513 chalcones Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 108010084210 citrin Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 2
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 2
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 2
- 238000011172 small scale experimental method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 235000017643 Elaeagnus angustifolia Nutrition 0.000 description 1
- 244000016119 Elaeagnus latifolia Species 0.000 description 1
- 235000001456 Elaeagnus latifolia Nutrition 0.000 description 1
- 235000007630 Elaeagnus umbellata var parvifolia Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 235000010829 Prunus spinosa Nutrition 0.000 description 1
- 240000004350 Prunus spinosa Species 0.000 description 1
- 241001480055 Quercus mongolica Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 125000004403 catechin group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- FCBUKWWQSZQDDI-UHFFFAOYSA-N rhamnolipid Chemical compound CCCCCCCC(CC(O)=O)OC(=O)CC(CCCCCCC)OC1OC(C)C(O)C(O)C1OC1C(O)C(O)C(O)C(C)O1 FCBUKWWQSZQDDI-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of Chinese medicines, and in particular to a kind of hippophae rhamnoides compositions, including hippophae rhamnoides and auxiliary material, the auxiliary material are alpha-lactose, mannitol or soluble starch.The present invention is made hippophae rhamnoides compositions particle and has excellent stability, and hydroscopicity is low.
Description
Technical field
The present invention relates to a kind of hippophae rhamnoides compositions and its preparation method and application.
Background technique
Sea-buckthorn also known as arrow-leaved oleaster, fructus hippophae, black thorn, acid thorn；Fruit shapes are subsphaeroidal or oval, and sea-buckthorn distribution is extremely wide,
It is all distributed in the temperate zone of two hemispheres to the torrid zone；Northwest, North China, each provinces and regions in southwest in China are also distributed, and China possesses the world
Upper the most abundant sea buckthorn resources.In fructus hippophae in addition to containing protein, fat, carbohydrate, there are also a variety of necessary to human body
Vitamin and inorganic salts, wherein vitamin content is abundant, including VB1, VB2, VB6 (folic acid), VC, VE, VK (phylloquinone), VP and
Carotenoid etc.；Especially it is height with VC content, almost occupies the hat of all fruits and vegetables, it may be up to 800 containing VC in every hectogram fructus hippophae~
1907mg reaches as high as 2100mg or more.In addition, Hippophae (rhamnoides) original juice also contains VK1, VA, VB1, VB2, it is husky in all berries
Vitamin content highest in spine, therefore have the title of " vitamin treasure-house ".Sea-buckthorn citrin powder is catechin, white anthocyanidin, cyanine
The general designation of element, flavones, flavonols, chalcone, deoxidation chalcone, fragrant glycosides and phenolic acid.Sea-buckthorn citrin powder used in the present invention
Middle Vc content is up to 5000mg/L, additionally has strengthen immunity, improves growth and development function, improves anoxia endurance function
Can, reducing blood lipid, function of blood sugar reduction are assisted, lead-expelling function etc. is promoted.It is mainly used for health food, functional food ingredient, common
Raw-food material, pharmaceutical raw material etc..
It is applied for many years through clinical, sea-buckthorn particle is curative for effect to illnesss such as relieving cough and reducing sputum, chronic bronchitis, sea-buckthorn particle
System uses the auxiliary materials such as hippophae rhamnoides and sucrose, microcrystalline cellulose, gelatin, glycerol, vegetable oil, magnesium stearate, ethyl cellulose
Compatibility is made.But this sea-buckthorn particle still has that hygroscopicity is strong, and particle is unstable, the low problem of ratio of briquetting.
Application No. is a kind of cough-relieving apophlegmatic of 200810046037.2 patent application, relieving dyspepsia, promoting blood circulation to remove blood stasis drug
And preparation method thereof, it discloses using solid content rhamnoides extract, mannitol, dextrin, soluble starch, Steviosin preparation sea-buckthorn class
Drug, it is big that there are supplementary product consumptions, at high cost, the problem of preparation process complexity.
Summary of the invention
The present invention in order to solve the problems existing in the prior art, provides a kind of hippophae rhamnoides compositions and its preparation method and application.
Hippophae rhamnoides compositions are mainly prepared by hippophae rhamnoides and pharmaceutically acceptable auxiliary material.
Applicants have found that supplementary product kind and dosage have apparent shadow to the stability and ratio of briquetting of hippophae rhamnoides compositions
It rings, the excessive hygroscopicity enhancing that will cause hippophae rhamnoides compositions of supplementary product consumption causes stability to decline, supplementary product kind will affect sand more
The mouthfeel of spine particle.
For applicant by experimental study, the auxiliary material that the hippophae rhamnoides compositions are selected is selected from alpha-lactose, mannitol or solubility
Starch, finished product all have excellent stability, and hydroscopicity is low, and small on the influence of finished product mouthfeel, remain Leaves of Hippophae L
Original taste.
In present invention experiment, when auxiliary material is selected from mannitol, the ratio of briquetting highest of finished product, and hydroscopicity is minimum.
In present invention experiment, when the mass ratio of the hippophae rhamnoides and auxiliary material is 1:1-2, be conducive to improve product at
Type rate.Preferably, the mass ratio of the hippophae rhamnoides and auxiliary material is 1:2.
Hippophae rhamnoides of the present invention uses the method including the following contents to be prepared: Leaves of Hippophae L is crushed into powder,
Extracting in water at least 1 time, filtering and merging gained filtrate is sea-buckthorn extracting solution, and sea-buckthorn extracting solution is concentrated, drying crushes
Obtain hippophae rhamnoides.Further, the solid-liquid ratio 1:6-16 of the Leaves of Hippophae L and water, when single-trial extraction a length of 1-4h, extract
Number is 3-4 times.In the embodiment of the present invention, the solid-liquid ratio of the Leaves of Hippophae L and water is selected from 1:12, and single-trial extraction duration is selected from 1h,
Extraction time is selected from 3 times.It should be known that gained filtrate is directly entered subsequent handling operation, no conjunction when extraction time is 1 time
And treatment process.
Further, the relative density of obtained medicinal extract is 1.29-1.33g/ml after the sea-buckthorn extracting solution is concentrated；Institute
Stating drying temperature is 70 DEG C.
The hippophae rhamnoides compositions are used to prepare the purposes of health care product or food additives.Above-mentioned health care product or food addition
Agent, also containing the different available auxiliary materials or carrier using dosage form of adaptation.Health care product is tablet, capsule or oral solution.
The present invention also provides a kind of preparation methods of hippophae rhamnoides compositions, take hippophae rhamnoides, auxiliary material, and adhesive is added,
Through granulation, drying, whole grain to obtain the final product.
In present invention experiment, former, the auxiliary material quality summation and adhesive volume ratio are 6-10:1wt:vol.Preferred mass
When volume ratio is 6:1, obtained hippophae rhamnoides compositions ratio of briquetting highest, hydroscopicity is minimum, stability is best.
In present invention experiment, adhesive is selected from the ethyl alcohol that mass concentration is 70-90%.Adhesive is selected from mass concentration
When 90% ethyl alcohol, the ratio of briquetting highest of hippophae rhamnoides compositions.
The invention has the advantages that:
One, the hydroscopicity of the obtained hippophae rhamnoides compositions particle of the present invention is low, improves granule stability, guarantees curative effect, uses
The combination of extract dry powder and auxiliary material can effectively reduce the dosage of auxiliary material compared to the combination for directlying adopt medicinal extract and auxiliary material, save
Cost.
Two, single auxiliary material is selected, it is more simple and efficient in the preparation, compared to multiple auxiliary materials, the dose of single auxiliary material
It reduces, but effect is identical, reduces the loss that supplementary product kind excessively causes Leaves of Hippophae L original flavor, as far as possible reservation Leaves of Hippophae L itself
Taste, especially when auxiliary material be selected from mannitol when, also have certain flavoring effect, sea-buckthorn folic acid can be alleviated in a certain range
Puckery mouthfeel, more preferably to user's experience sense.
Three, the present invention selects ethyl alcohol as adhesive, and grain forming can be made good, and property is stablized, compared to water
As adhesive, the generation of agglomeration and the excessive situation that can not be sieved of viscosity is effectively prevented.
Four, the obtained hippophae rhamnoides compositions particle of the present invention, packing dosage is small, and taking dose is few, is suitble to crowd wide, especially just
It is applied in children, is also convenient for carrying.
Five, the present invention can be used for health care product, food additives, be widely used.
Detailed description of the invention
Fig. 1 is that 3 batch Leaves of Hippophae L particle pictorial diagrams are made；
Fig. 2 is Particles at Critical relative humidity figure；
Fig. 3 is granule production technological process.
Specific embodiment
Below by specific embodiment, the present invention is described in further detail, and following embodiment can make this profession
The present invention, but do not limit the invention in any way is more completely understood in technical staff.
One, instrument and material
1.1 instrument
HH-2 digital display thermostat water bath (Guo Hua Electrical Appliances Co., Ltd)；METTLERAE240 electronic analytical balance；KQ-250B
Type ultrasonic cleaner (Kunshan ultrasonic instrument Co., Ltd)；IKARV10 type Rotary Evaporators (the Chinese mugwort limited public affairs of card instrument and equipment
Department)；Waters AcquityH-Class Ultra Performance Liquid Chromatography instrument (Waters, US).
1.2 materials and reagent
Chromatography methanol (Fischer company), chromatography phosphoric acid (Tianjin Kermel Chemical Reagent Co., Ltd.)；Ultrapure water.
Quercetin (lot number: 16022301, Chengdu Kang Bang Biotechnology Co., Ltd), Kaempferol (lot number: 15120415, Chengdu health nation
Biotechnology Co., Ltd), Isorhamnetin (lot number: 15100348, Chengdu Kang Bang Biotechnology Co., Ltd), purity >=
98%.Food-grade alpha-lactose, soluble starch, dextrin, mannitol, xylitol, glucose (the limited public affairs of Zhengzhou Zhuo Yan biotechnology
Department).
Two, method and result
The selection of 2.1 dosage forms
Larger, the piece in conjunction with Leaves of Hippophae L pharmacological effect, reactive compound physicochemical property and holding conditions and decoction dose
The preservative toxicity of tabletting, coating and the mixture of agent and oral solution, corrigent prepare the unfavorable factors such as complexity, and granule phase
The advantages that few to supplementary product consumption, easy to process, convenient for storage carrying, therefore dosage form is determined as granule.
2.2 extraction process routes are drafted
The extracted obtained Leaves of Hippophae L Aqueous extracts of Leaves of Hippophae L are concentrated under reduced pressure, are dried to obtain extract powder, are added auxiliary material obtained
Grain, then got product through whole grain, packing.
2.3 Study on extraction
Chinese medicine extraction process ensures the important link of resource utilization He the effective drug effect of its preparation safety, early-stage study table
It is highly polar flavone compound in aglycon that main active, which is Quercetin, Kaempferol, Isorhamnetin etc., in bright Leaves of Hippophae L,
Therefore this granule raw material is extracted using the stronger pure water of polarity, is to refer mainly to Quercetin, Kaempferol, Isorhamnetin content
Mark, and using paste-forming rate as auxiliary characteristics, determine optimum extraction process.
2.3.1 single factor exploration
The influence of solid-liquid ratio: precision weighs 3 parts of Leaves of Hippophae L powder respectively, and every part of 5g is set in round-bottomed flask, presses feed liquid respectively
Add pure water than 1:6,1:8,1:10,1:12,1:16, extracts 1h, filtering, merging filtrate is spin-dried for, using superelevation liquid chromatography
Quercetin, Kaempferol, Isorhamnetin content are measured, and paste-forming rate is calculated according to the following formula.It the results are shown in Table 1.
Paste-forming rate (%)=dry cream quality/quality of medicinal material × 100%
1 solid-liquid ratio of table is investigated
Table 1 Investigation of the ratio of material to liquid
As can be seen from the results, generally with the increase of amount of water, Quercetin, Kaempferol, the content of Isorhamnetin and cream out
Rate is consequently increased, and the content of especially Isorhamnetin significantly improves, based on the factors such as convenient degree and cost of extraction, using feed liquid
It is extracted than 1:12.
The investigation of extraction time: precision weighs 4 parts of Leaves of Hippophae L powder respectively, and every part of 5g is set in round-bottomed flask, and 60mL is added
Water extracts 1h, 2h, 3h, 4h respectively, and filtering, merging filtrate is spin-dried for, using superelevation liquid chromatography for measuring Quercetin, kaempferia galamga
Phenol, Isorhamnetin content simultaneously calculate paste-forming rate.It the results are shown in Table 2.
2 extraction time of table is investigated
Table2 Investigation of the extraction time
As can be seen from the results, with the increase of extraction time, Quercetin, the content of Isorhamnetin and paste-forming rate also increase, but
Increase is not obvious, to prevent the extraction time too long active constituent that may be destroyed in Leaves of Hippophae L and saving the factors such as time,
Use extraction time for 1h.
The investigation of extraction time: precision weighs 4 parts of Leaves of Hippophae L powder respectively, and every part of 5g is set in round-bottomed flask, and 60mL is added
Water extracts 1 time, 2 times, 3 times, 4 times respectively, and each 1h, filtering, merging filtrate is spin-dried for, using superelevation liquid chromatography for measuring Mongolian oak
Pi Su, Kaempferol, Isorhamnetin content simultaneously calculate paste-forming rate.It the results are shown in Table 3.
3 extraction time of table is investigated
Table 3 Investigation of the times of extraction times
As can be seen from the results, with the increase of extraction time, Quercetin, Kaempferol, the content of Isorhamnetin and paste-forming rate
Increase therewith, Isorhamnetin content increase is especially significant, and in the 3rd extraction, the content and paste-forming rate of three compounds are basic
Reach saturation, increase trend tends to be steady, therefore uses 3 decoctions.
Wherein, the chromatographic condition of superelevation liquid chromatography are as follows: chromatographic column ACQUITYHSS C18(2.1mm
× 100mm, 1.8 μm)；Mobile phase is methanol (A) -0.2% phosphoric acid water (B), elution program are as follows: 0-3min, 5%-10%A；3-
7min, 10%-25%A；7-13min, 25%-48%A；13-17min, 48%-51%A；17-32min, 51%A-51%A；
30 DEG C of column temperature；0.15 mLmin of flow velocity-1；Sample volume: 3 μ L；Detection wavelength 370nm.
Above-mentioned superelevation liquid phase chromatogram condition is through methodological study, measurement result accurate and effective.
2.3.2 orthogonal experiment
In Leaves of Hippophae L flavone compound Quercetin, Kaempferol, the content of Isorhamnetin and paste-forming rate by solid-liquid ratio, decoct
The influence of many factors such as time and extraction time is boiled, therefore, using Orthogonal Decomposition contrived experiment, to quercitrin in influence Leaves of Hippophae L
Element, Kaempferol, Isorhamnetin content and paste-forming rate factor investigated comprehensively.
Quadrature factor level design: 4 are shown in Table, Orthogonal Experiment and Design and result, correlation analysis are shown in Table 5,6,7,8,9.
4 factor level table of table
Table 4 Level of factors
5 Orthogonal experiment results table of table
Table 5 The results oforthogonal experimental
6 paste-forming rate variance interpretation of result of table
Table 6 Analysis ofvariance results ofointment rate
7 quercetin content variance analysis of results table of table
Table 7 Analysis ofvariance results ofquercetin content
8 kaempferia galamga phenol content variance interpretation of result of table
Table 8 Analysis ofvariance results ofkaempferol content
9 Isorhamnetin content variance interpretation of result of table
Table 9 Analysis ofvariance results ofISO rhamnolipid content
Interpretation of result: according to orthogonal experiment and variance interpretation of result it is found that paste-forming rate degree of susceptibility is followed successively by extraction time
(C) > solid-liquid ratio (A) > extraction time (B), optimal combination A2B3C3；In quercetin content measurement, influence degree is followed successively by
Extraction time (C) > extraction time (B) > solid-liquid ratio (A), optimal combination A3B1C3；In Kaempferol assay, extract secondary
Number (C) > solid-liquid ratio (A) > extraction time (B), optimal combination A1B2C3；In Isorhamnetin assay, influence degree according to
Secondary is extraction time (C) > extraction time (B) > solid-liquid ratio (A), optimal combination A3B1C3.It can by above-mentioned analysis result
Know, three solid-liquid ratio (A), extraction time (B), extraction time (C) factor differences are not significant, since extraction time (C) is at 3
It plays main influence in inspection target, therefore extraction time is determined as 3 times, in conjunction with single factor exploration experimental result, really
Determine optimum extraction process are as follows: A3B1C3, i.e. solid-liquid ratio be 1:12, extraction time 1h, extraction time 3 times.
2.3.3 verification test
Precision weighs 3 parts of Leaves of Hippophae L powder, every part of 100g, according to optimal conditions parallel extraction 3 times of above-mentioned determination, to out
Cream rate, Quercetin, Kaempferol, Isorhamnetin content are measured, the results showed that the extraction process is stablized feasible.
10 verification test result of table
Table 10 The results of verification experiment
2.4 concentrations and drying process research
2.4.1 concentration technology is investigated
In pelletization, the medicinal extract obtained after medicinal material extract concentration is one of the key technology for determining preparation process, generally
Using the relative density of medicinal extract as evaluation index, relative density is bigger, and medicinal extract is more sticky, and required auxiliary material is fewer when granulation, conversely,
Relative density is smaller, and medicinal extract is thinner, and mobility is stronger, and required auxiliary material is more, therefore, by measuring relative density, investigates husky
The concentrating degree of spine leaf medicinal extract, determines best concentration technology.Take the sea-buckthorn leaf extract under " 2.3.3 " item in " verification test "
100,200,300,350,400mL were compared in version " Chinese Pharmacopoeia " the 4th (general rule 0601) relative density determination method by 2015
Weight bottle method (2) method is measured, and the results are shown in Table 11.
The relative density of test sample=test sample weight/water weight
11 concentration technology of table investigates result table
Table 11 Table of results of concentration process
By investigation result it is found that being 1.29-1.33g.mL when sea-buckthorn leaf extract is concentrated into relative density-1Medicinal extract when,
Concentrating degree is suitable for that medicinal extract is viscous pasty state, is easy to topple over and without wall built-up phenomenon.
2.4.2 drying process is investigated
Binding experiment room relevant device condition, using traditional oven drying method as the drying mode of Leaves of Hippophae L medicinal extract, and is investigated out
Cream rate and Quercetin, Kaempferol, Isorhamnetin content, further verify technology stability.By the Leaves of Hippophae L under " 2.3.3 " item
It is 1.29-1.33g.mL that extracting solution normal pressure, which is concentrated into relative density,-1Medicinal extract, weigh 3 parts of medicinal extract, every part of about 30g is dried in 70 DEG C
It dries in case to constant weight, sets accurately weighed after cooling in drying basin, calculating paste-forming rate, dry cream is finely ground, No. 3 sieves are crossed, fine powder is taken
0.5g measures Quercetin, Kaempferol, Isorhamnetin content by chromatographic condition under " 2.3.1 " item, the results are shown in Table 12.
12 drying process of table investigates result table
Table 12 Table of results of drying process
Paste-forming rate, quercitrin by investigation result it is found that using oven drying method when being dried for 70 DEG C, to Leaves of Hippophae L medicinal extract
Element, Kaempferol, Isorhamnetin content have no significant effect, and illustrate that the drying mode is effective and feasible.
2.5 Study on Forming
2.5.1 the preparation of extract powder
The dry blade powder 12kg of sea-buckthorn is taken, is decocted with water, by solid-liquid ratio 1:12 (ml:g) plus pure water, decoction 3 times, often
Secondary 1h, filtering, merging filtrate are simultaneously concentrated into relative density as 1.29-1.33g.mL-1Thick medicinal extract, dried in 70 DEG C of baking ovens,
Leaves of Hippophae L dry cream is obtained, is crushed, crosses No. 3 sieves to get Leaves of Hippophae L extract powder.
2.5.2 the initial option of auxiliary material
It is auxiliary to soluble starch, alpha-lactose, mannitol, dextrin, xylitol, glucose etc. using hydroscopicity as inspection target
Material carries out initial option.The glass desicator that bottom is filled NaCl supersaturated solution makes it in placing 48h in 25 DEG C of baking ovens
Internal relative humidity (RH) is 75%.Each auxiliary material about 1g is weighed respectively, is respectively put into and has been dried into the weighing bottle of constant weight, gently
Shaking makes it be evenly distributed, and spreading out to thickness is about 2mm, and after accurately weighed, it is dry for 75% glass to be put into internal relative humidity (RH)
In dry device, bottle cap is opened, is placed in 25 DEG C of baking ovens, is weighed respectively in 2,4,8,12,24,48h], by formula: hydroscopicity %
=(medicinal powder quality-moisture absorption prodrug silty amount after moisture absorption)/moisture absorption prodrug silty amount × 100% calculates hydroscopicity, the results are shown in Table
13。
Hydroscopicity of each auxiliary material of table 13 in the environment of RH75%
Table 13 The moisture absorption rate of the excipients in the
Environment of RH 75%
From the data in the table, the hydroscopicity of xylitol is apparently higher than other auxiliary materials, be unfavorable for granule stability and
It saves, and expensive；Glucose hydroscopicity is higher, and contains higher sugar, is unfavorable for the patients' such as diabetes, hypertension
It takes.Comprehensively consider, tentatively selected alpha-lactose, mannitol and dextrin, soluble starch carry out preliminary experiment as auxiliary material.
2.5.3 auxiliary material preliminary experiment
20g Leaves of Hippophae L extract powder is taken, by extract powder: auxiliary material (1:2) forms sediment with alpha-lactose, mannitol, dextrin, solubility respectively
Powder mixing is crossed No. 3 sieves and is uniformly mixed, and using 80% ethyl alcohol as adhesive softwood, crosses No. 1 sieve granulation, particle is done at 70 DEG C
Dry and whole grain selects best auxiliary material using the hygroscopicity of particle, mouldability, angle of repose and dissolubility as inspection target, carries out next
Orthogonal test is walked, determines the best preparation process of Leaves of Hippophae L granule.
The measurement of particle hydroscopicity: the glass desicator that bottom fills NaCl supersaturated solution is placed in 25 DEG C of baking ovens
48h, the relative humidity (RH) for keeping it internal is 75%.About 1g particle obtained above is weighed, is respectively put into and has dried to constant weight
Weighing bottle in, jog makes it be evenly distributed, and thickness is about 2mm, be put into after accurately weighed internal relative humidity (RH) be 75%
In glass desicator, bottle cap is opened and is taken out after 25 DEG C of baking ovens place 48h, accurately weighed, by formula: hydroscopicity %=(inhales
Medicinal powder quality-moisture absorption prodrug silty amount after wet)/moisture absorption prodrug silty amount × 100%, particle hydroscopicity is calculated, the results are shown in Table
14。
Grain forming rate measurement: take particle 30g obtained above respectively, according to 2015 version " Chinese Pharmacopoeia " to granule
Granularity requirements, respectively by No. 1 sieve and No. 5 sieves, wherein the summation that cannot be sieved and can be sieved by No. 5 by No. 1 is no more than
15%.By formula: ratio of briquetting %=can pass through No. 1 sieve and particle weight/particle total weight × 100% that cannot be sieved by No. 5, meter
Ratio of briquetting is calculated, the results are shown in Table 14.
Fluidity determining: it using angle of repose (α) as the evaluation index of mobility of particle, is surveyed using fixed funnel method
It is fixed, a graph paper is placed in the horizontal plane, and 3 funnel series connection are fixed on iron stand, make funnel bottom end away from graph paper height
Spending (h) is 1cm, and particle obtained above is fallen down along top funnel wall, until hopper base termination contacts the particle on graph paper
Until cone tips, cone bottom radius (r) is measured using graph paper, angle of repose is calculated, the results are shown in Table 14.Angle of repose:
Tan α=h/r
Melting measurement: according to 2015 version " Chinese Pharmacopoeia " take test sample 10g, heat water 200ml, stir 5min, stand
Observation is carved, particle should all dissolve or slight turbid, the results are shown in Table 14.
14 particle hydroscopicity of table, ratio of briquetting, melting investigate result table
Table 14 Investigation results ofmoistureabsorption,molding rate and
solubility of particles
As preliminary experiment it is found that using dextrin as particle made from auxiliary material, hydroscopicity is higher than other auxiliary materials, and ratio of briquetting only has
10.05%, and have that apparent caking phenomenon, viscosity is big, is difficult to granulation of being sieved, therefore mobility and melting can not be investigated；α-cream
Sugar, mannitol and soluble starch are particle made from auxiliary material, and hydroscopicity, ratio of briquetting and melting meet States Pharmacopoeia specifications, and
Angle of repose illustrates that particle has good mobility less than 40 °, in summary as a result, selection alpha-lactose, soluble starch and sweet dew
Alcohol carries out orthogonal test as auxiliary material, preferably best preparation process out.
2.5.4 orthogonal test preferred formulation technique
Experimental design: using grain forming rate as index, supplementary product kind (A), supplementary material ratio (B), concentration of alcohol are investigated
(C), influence of 4 factors of ethanol consumption (D) to grain forming rate, wherein ethanol consumption (D) with former, auxiliary material quality summation with
Ethyl alcohol volume ratio indicates, chooses L9(34) orthogonal table contrived experiment, preferably best preparation process out.Quadrature factor level design
It is shown in Table 15.
15 factor level of table
Table 15 The level of factors
Orthogonal Experiment and Design and result: 16 are shown in Table, variance analysis is shown in Table 17.
16 Orthogonal experiment results of table
Table 16 The results of orthogonal experimental
17 the results of analysis of variance of table
Table 17 The results ofvariance analysis
As can be seen from the results, when auxiliary material is mannitol, the ratio of briquetting of particle is higher than other auxiliary materials, the influence degree of each factor
It is followed successively by supplementary product kind (A) > supplementary material ratio (B) > concentration of alcohol (C) > ethanol consumption (D), since ethanol consumption is to particle
The influence of ratio of briquetting is minimum, therefore carries out variance analysis as error, the results showed that, the type and supplementary material ratio of auxiliary material
Significant difference between each level.In conclusion determining that the best preparation process of Leaves of Hippophae L particle is A1B3C3D3, i.e., with mannitol
For auxiliary material, dosage is 2 times of raw material, using 90% ethyl alcohol as adhesive, the mass body of raw material and auxiliary material quality summation and ethyl alcohol
Product is than being 6:1.
Applicant is also raw material to the medicinal extract directlyed adopt after being concentrated, and auxiliary material is added and prepares hippophae rhamnoides compositions particle, former, auxiliary
Material ratio is 1:5.The application is easier to save using Leaves of Hippophae L extract powder as raw material compared to rhamnoides extract one side raw material, storage
Time extension is deposited, property is more stable, on the other hand can reduce the dosage of auxiliary material, and former, auxiliary material proportion 1:2 can be reduced into
This.
2.5.5 verification test
Extract powder 30g obtained under " 2.5.1 " item is taken, is made in parallel by the optimum process condition A1B3C3D3 of above-mentioned determination
3 batches of Leaves of Hippophae L particles are obtained, the ratio of briquetting for measuring particle is respectively 95.67%, 94.91%, 96.18%, RSD 0.67%, table
The bright stable preparation process is reliable.
2.5.6 the measurement of Particles at Critical relative humidity (CRH)
The hygroscopicity of drug has a major impact the quality and stability of preparation.Moisture absorption is the characteristic of solid pharmaceutical preparation, is faced
Boundary's relative humidity (CRH) is the hygroscopic index value of drug, and CRH value is smaller, shows that drug hygroscopicity is stronger, otherwise CRH bigger,
Drug is less susceptible to moisture absorption.There are many hydrophilic compositions, easily moisture absorption in Chinese materia medica preparation, therefore measure CRH size, evaluates accordingly
The size of relative humidity (RH) provides reference in the production process of Chinese materia medica preparation.
Using the CRH of powder moisture absorption method measurement Leaves of Hippophae L particle, by various concentration H2SO4With the satiety of various concentration NaCl
It is placed on glass desicator bottom with solution, places 48h in 25 DEG C of baking oven, drier internal relative humidity is made to reach flat
Weighing apparatus, takes in " 2.5.5 " 14 parts of Leaves of Hippophae L particle prepared under " verification test " item, and every part of about 1g is placed in dry to constant weight
Weighing bottle in, two parts are put in each drier, jog makes it be evenly distributed, and spreading out to thickness is about 2mm, accurately weighed, beats
Weigh the cap is opened, places 48h in 25 DEG C of baking ovens, it is accurately weighed after taking-up, calculate the suction of Leaves of Hippophae L particle under various circumstances
Wet rate, the results are shown in Table 18.Moisture percentage (%) with particle is ordinate, relative humidity (RH) is that abscissa draws curve,
The critical relative moisture (CRH) that particle is determined by the abscissa of the curve both ends point of intersection of tangents, is as a result shown in Fig. 2.
18 particle hydroscopicity of table and various concentration sulfuric acid and salt relative humidity investigation table
Table 18 Investigation of the moisture absorption rate and the
relative humidity of sulphuric acid and salt with different concentrations
As seen from the figure, 25 DEG C when, the critical humidity of Leaves of Hippophae L particle is 70%, is illustrated under this condition, the physics of particle
Property is stablized, and therefore, during preparing particle, should control wettability 70% hereinafter, storage and storage in favor of particle,
Guarantee the stability of particle.
The determination of 2.6 Leaves of Hippophae L particle sizes
Referring in 2015 version " Chinese Pharmacopoeia " also based on the derivative of the aglycons such as Quercetin, Kaempferol and Isorhamnetin
Related specification under " capsule of ginkgo leaves " item of active material is wanted, " capsule of ginkgo leaves " determines Quercetin, Kaempferol and different sandlwood
Cellulose content, and according to formula: total flavonoids content=(quercetin content+kaempferia galamga phenol content+Isorhamnetin content) × 2.51,
General flavone glycoside content is converted into as assay index, it is specified that every content containing general flavone glycoside must not less than 19.2mg,
3 times a day, 1-2 each.This experiment is as referring to foundation.By " verification test " in " 2.3.3 " it is found that pressing best work
The Leaves of Hippophae L that skill the is extracted paste-forming rate that be averaged is 20.72%, Quercetin in the Leaves of Hippophae L of Unit Weight, Kaempferol, Isorhamnetin
Average content is respectively 1.33mg.g-1、0.43mg.g-1、6.67mg.g-1, Quercetin, Kaempferol and Isorhamnetin it is average total
Content is 8.4mg.g-1, being scaled total flavonoids content is 21.2 mg.g-1, therefore, the specification of Leaves of Hippophae L particle is set to
1.5g/ bags, 2 times a day.
2.7 process flow chart
Detailed process is detailed in attached drawing 3.
2.8 prescription small-scale experiments
By above-mentioned optimum extraction process and preparation process, Leaves of Hippophae L particle is prepared, prepares 3 batches of samples, every batch of in parallel
1000g carries out small-scale experiment, 3 batches of sample datas of gained and run-of-the-mill inspection result, is shown in Table 19 and 20.
193 batches of sample experimental results of table
Table 19 Experimental results of 3 samples
20 3 batches of sample survey results of table
Table 20 Test results of 3 samples
In order to further verify the stability of Leaves of Hippophae L granule formation technology, it is small to have carried out prescription for Binding experiment room condition
It has a try and tests, the results showed that, 3 batches of laboratory sample parameters are consistent, meet requirements under " Chinese Pharmacopoeia " granule item,
Illustrate that the process stabilizing is feasible, can in high volume put into production.
The above description is merely a specific embodiment, but scope of protection of the present invention is not limited thereto, any
Those skilled in the art within the technical scope disclosed by the invention, can without the variation that creative work is expected or
Replacement, should be covered by the protection scope of the present invention.Therefore, protection scope of the present invention should be limited with claims
Subject to fixed protection scope.
Claims (10)
1. a kind of hippophae rhamnoides compositions, it is characterised in that: including hippophae rhamnoides and auxiliary material, the auxiliary material is alpha-lactose, mannitol
Or soluble starch.
2. hippophae rhamnoides compositions according to claim 1, it is characterised in that: the auxiliary material is selected from mannitol.
3. hippophae rhamnoides compositions according to claim 1, it is characterised in that: the mass ratio of the hippophae rhamnoides and auxiliary material is 1:
1-2；Preferably 1:2.
4. hippophae rhamnoides compositions according to claim 1, which is characterized in that the preparation method of the hippophae rhamnoides, including with
Lower content: Leaves of Hippophae L is crushed into powder, and extracting in water at least 1 time, filtering and merging gained filtrate is sea-buckthorn extracting solution, will be husky
Spine extracting solution is concentrated, dry, crushing obtains hippophae rhamnoides.
5. hippophae rhamnoides compositions according to claim 4, it is characterised in that: the solid-liquid ratio 1:6-16 of the Leaves of Hippophae L and water, it is single
A length of 1-4h when secondary extraction, extraction time are 3-4 times；Preferably, the solid-liquid ratio of the Leaves of Hippophae L and water is selected from 1:12, and single mentions
Duration is taken to be selected from 1h, extraction time is selected from 3 times.
6. hippophae rhamnoides compositions according to claim 4, it is characterised in that: obtained medicinal extract after the sea-buckthorn extracting solution is concentrated
Relative density is 1.29-1.33g/ml；The drying temperature is 70 DEG C.
7. the purposes that any hippophae rhamnoides compositions of claim 1-6 are used to prepare health care product or food additives.
8. a kind of preparation method of hippophae rhamnoides compositions, it is characterised in that: take hippophae rhamnoides, auxiliary material, adhesive is added, through making
Grain, dry, whole grain to obtain the final product.
9. the preparation method of hippophae rhamnoides compositions according to claim 8, it is characterised in that: the raw material and auxiliary material summation and viscous
Mixture mass volume ratio (wt:vol) is 6-10:1.
10. the preparation method of hippophae rhamnoides compositions according to claim 8, it is characterised in that: described adhesive is mass concentration
For the ethyl alcohol of 70-90%；The ethyl alcohol that preferred mass concentration is 90%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810343377.5A CN110384720A (en) | 2018-04-17 | 2018-04-17 | A kind of hippophae rhamnoides compositions and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810343377.5A CN110384720A (en) | 2018-04-17 | 2018-04-17 | A kind of hippophae rhamnoides compositions and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110384720A true CN110384720A (en) | 2019-10-29 |
Family
ID=68283146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810343377.5A Pending CN110384720A (en) | 2018-04-17 | 2018-04-17 | A kind of hippophae rhamnoides compositions and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110384720A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813827A (en) * | 2005-02-04 | 2006-08-09 | 向云成 | Sea-buckthorn chewing tablet and its preparation |
| CN102058631A (en) * | 2010-12-22 | 2011-05-18 | 天津泰阳制药有限公司 | Seabuckthorn leaf extract preparation and preparation method thereof |
| CN105412255A (en) * | 2015-08-26 | 2016-03-23 | 新疆环拓生物科技有限公司 | Anti-fatigue quick-smoking troche and preparation method thereof |
| CN107823150A (en) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | It is a kind of can rapid dispersion tablet and preparation method thereof |
-
2018
- 2018-04-17 CN CN201810343377.5A patent/CN110384720A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813827A (en) * | 2005-02-04 | 2006-08-09 | 向云成 | Sea-buckthorn chewing tablet and its preparation |
| CN102058631A (en) * | 2010-12-22 | 2011-05-18 | 天津泰阳制药有限公司 | Seabuckthorn leaf extract preparation and preparation method thereof |
| CN105412255A (en) * | 2015-08-26 | 2016-03-23 | 新疆环拓生物科技有限公司 | Anti-fatigue quick-smoking troche and preparation method thereof |
| CN107823150A (en) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | It is a kind of can rapid dispersion tablet and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张媛: "《中药制剂技术》", 31 August 2012, 河南科学技术出版社 * |
| 滕晓萍: "《沙棘叶研究进展综述》", 《国际沙棘研究与开发》 * |
| 陆彬: "《药剂学》", 31 January 2003, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105056092B (en) | A kind of preparation method of granule containing ginseng, Siberian cocklebur, lagehead atractylodes and its granule containing ginseng, Siberian cocklebur, lagehead atractylodes of preparation | |
| CN101961422B (en) | Extractive of Pu'er tea and preparation method thereof | |
| CN100533140C (en) | Checking method for depression relieving and tranquilizing preparation | |
| CN102423352B (en) | Preparation method of Chinese medicinal granules for treating cardio-cerebrovascular diseases | |
| CN107050304A (en) | A kind of preparation method of the brave fruit Chinese herbal granules of the rock of Sugarless type two | |
| CN111358839B (en) | Formula granules of polygonum capitatum and preparation method thereof | |
| CN108362788A (en) | A kind of steamed sealwort Quality Detection analysis method | |
| CN104116963B (en) | A kind of radix fici simplicissimae compound preparation and preparation method thereof for resisting oxidation and delaying senility | |
| CN101757099A (en) | Desmodium-capillary artemisia cholecystagogue, preparation method and quality control method thereof | |
| CN107115460A (en) | David's-harp compound granules and preparation method thereof | |
| CN101485735B (en) | Medicament composition with stone-eliminating and expelling functions and preparation method thereof | |
| CN103550398B (en) | Composition for relieving fatigue as well as preparation method and medical application thereof | |
| CN104998071A (en) | Compound preparation ofherb of dense flower Bulbophyllum and preparation and detection method for said compound preparation | |
| CN105031005A (en) | Micro pills capable of tonifying qi and benefiting blood | |
| CN110269920A (en) | Alleviate the Traditional Chinese drug mixture and preparation method thereof of stomach disease | |
| CN101450137A (en) | Preparation method of anti-virus traditional Chinese medicine | |
| CN110384720A (en) | A kind of hippophae rhamnoides compositions and its preparation method and application | |
| CN113952419B (en) | Pharmaceutical composition for chronic renal failure and preparation method and application thereof | |
| CN104352940B (en) | A kind of Chinese medicine composition for alleviating physical fatigue | |
| CN108310119A (en) | A kind of Herba Cistanches chewable tablets and preparation method thereof | |
| CN101129540B (en) | Traditional Chinese medicine composition for strengthening the spleen and stomach and eliminating fullness and distension in the abdomen, and technique of preparing the same and application of the sam | |
| CN1695713B (en) | Medication for treating diabetes and preparation method and quality control method | |
| CN103446284A (en) | Traditional Chinese medicine compound granules for treating infantile asthma and preparation method thereof | |
| CN116570669B (en) | Method for treating diseases and Chinese medicinal composition used in same | |
| CN105079135B (en) | A kind of Chinese medicine composition and preparation method thereof for treating flu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191029 |